Seattle, Washington--(Newsfile Corp. - April 3, 2020) - CFN Media (OTCQB: CNFN), the leading agency and financial media network dedicated to the legalized North American cannabis industry announces publication of an article discussing investing in the psychedelic market.
Psilocybin
To view an enhanced version of this image, please visit:
Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a in the space.
In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how along with other public companies are positioning themselves in the psychedelic space.
A Growing Body of Evidence
A growing body of evidence supports the use of psychedelics to treat a variety of different medical conditions. In 2016, researchers found that psilocybin produced a substantial and sustained decrease in depression and anxiety in cancer patients. A follow-up study on the same patients five years later found lasting effects from the one-time therapy.
The therapeutic evidence has become so overwhelming that Johns Hopkins established the Center for Psychedelic and Consciousness Research earlier this year to start rigorously investigating the drugs' therapeutic potential. Researchers believe that it could have a beneficial impact on everything from smoking addiction to Alzheimer's disease.
In addition to medical benefits, there's plenty of anecdotal evidence that microdoses of psychedelics could improve mental health, well-being and productivity. Many prominent business leaders in Silicon Valley, including the late Steve Jobs, praised the benefits of microdosing psychedelics for creativity and cognition.
Decriminalization Gains Ground
The growing interest among researchers has bolstered attempts by activists to decriminalize psychedelics throughout the country. Denver, Oakland and Santa Cruz have already decriminalized psychedelics over the past year, while California, Oregon and Iowa could see psychedelic-related measures on the ballot in November.
In the nation's capital, Rep. Alexandria Ocasio-Cortez, D-NY recently introduced legislation that would allow researchers to more easily study the therapeutic and medicinal benefits of psilocybin and other psychedelics. These developments mirror what happened in the early medical cannabis industry where regulations were slowly relaxed over time.
It's worth noting that these early efforts seek to decriminalize psychedelics and pave the way for research. Unlike the cannabis industry, there's less interest in a recreational market and more interest in building a viable alternative therapy for countless different medical conditions that impact the brain-many without any current options.
Investors Start Taking Notice
Mind Medicine Inc., better known as MindMed, became the first psychedelic pharmaceutical company to go public earlier this year on the NEO exchange. After raising $24.2 million in pre-public funding, the company plans to initially focus on addressing the opioid crisis and other forms of addiction with the use of psychedelics.
is another publicly-traded company in the space. Its Mycotopia Therapy subsidiary recently acquired PsychedeliTech and plans on hosting an inaugural PsyTech Summit in Tel Aviv, Israel on June 14-15, 2020. The conference will be modeled after the highly-successful CannaTech conference and connect key industry participants.
New Dates: June 14-15
To view an enhanced version of this image, please visit:
The company believes that its Dash platform will play a crucial role in the global advancement of psychedelic research. As a HIPAA and GDPR compliant platform, Dash is secure and compliant with some of the world's strictest privacy laws. It's an optimal way to compile psychedelic research and results to provide easy access for scientists globally.
Looking Ahead
Psychedelics are quickly picking up steam among both researchers and investors. As the market opens up, are building an early presence in the space before it grows into a large and mainstream industry. Cannabis investors may want to consider building a position in some of these companies given the similarities.
Click here to read the full feature:
Ehave Contact:
Gabe Rodriguez
623-261-9046
CFN Media Contact:
President Frank Lane
206-369-7050
About CFN Media
(OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis industry.
For Visitors and Viewers
(CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.
For Cannabis Businesses & Companies
CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.
Our powerful digital media and distribution platform conveys a company's message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.
Since 2013, CFN Media has enabled the world's preeminent cannabis companies to thrive in the capital and public markets.
Learn how to become a CFN Media client company, brand or entrepreneur:
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation:
To view the source version of this press release, please visit
